Last reviewed · How we verify
COVID
COVID, developed by Hacettepe University, is a marketed small molecule therapeutic agent with an unknown mechanism of action. The key composition patent for COVID is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk is the uncertainty surrounding the drug's mechanism of action, which may limit its adoption and regulatory support.
At a glance
| Generic name | COVID |
|---|---|
| Sponsor | Hacettepe University |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
- Pain at injection site
- Fatigue
- Headache
- Chills
- Muscle pain
- Joint pain
- Fever
- Injection site swelling
- Injection site redness
Key clinical trials
- Impact Of Kidney Failure On The Regulation Of Humoral Response To Vaccination
- Is Swimming a More Tolerable Form of Movement for Individuals With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome? (NA)
- Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons
- Dendritic Cell Vaccine to Prevent COVID-19 (PHASE1)
- Evaluation of the Medentum Diagnostik Platform for Pediatric ENT Conditions and Asthma (NA)
- Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
- SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism (NA)
- Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COVID CI brief — competitive landscape report
- COVID updates RSS · CI watch RSS
- Hacettepe University portfolio CI